ArticleBMC genomics2015
Genome-wide expression analysis suggests a crucial role of dysregulation of matrix metalloproteinases pathway in undifferentiated thyroid carcinoma.
Article in BMC genomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- Loss of long-range co-expression is a common feature in cancer.NPJ systems biology and applications · 2026Article
- High Local and Systemic Expression of Pentraxin-3 in Anaplastic Thyroid Cancer.International journal of molecular sciences · 2025Article
- Amelioration of non-alcoholic fatty liver disease by targeting adhesion G protein-coupled receptor F1 (eLife · 2023Article
- Methylation-related genes involved in renal carcinoma progression.Frontiers in genetics · 2023Article
- The crossroad between autoimmune disorder, tissue remodeling and cancer of the thyroid: The long pentraxin 3 (PTX3).Frontiers in endocrinology · 2023Review
- Integrated analysis of novel macrophage related signature in anaplastic thyroid cancer.Endocrine · 2022Article
- Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in colorectal cancer.Stem cell research & therapy · 2022Article
- In Vitro and In Vivo Effects of the Urokinase Plasminogen Activator Inhibitor WX-340 on Anaplastic Thyroid Cancer Cell Lines.International journal of molecular sciences · 2022Article
- Whole genome analysis reveals the genomic complexity in metastatic cutaneous squamous cell carcinoma.Frontiers in oncology · 2022Article
- Construction of a Signature Model to Predict the Radioactive Iodine Response of Papillary Thyroid Cancer.Frontiers in endocrinology · 2022Article
- The DPP-IV inhibitor saxagliptin promotes the migration and invasion of papillary thyroid carcinoma cells via the NRF2/HO1 pathway.Medical oncology (Northwood, London, England) · 2020Article
- Article
- The Emerging Role of Adhesion GPCRs in Cancer.ACS pharmacology & translational science · 2020Review
- The Long Pentraxin PTX3 as a Link Between Innate Immunity, Tissue Remodeling, and Cancer.Frontiers in immunology · 2019Review
- Genetic expression profile-based screening of genes and pathways associated with papillary thyroid carcinoma.Oncology letters · 2018Article
- A transcriptome-based protein network that identifies new therapeutic targets in colorectal cancer.BMC genomics · 2017Article
- RNA-Seq based genome-wide analysis reveals loss of inter-chromosomal regulation in breast cancer.Scientific reports · 2017Article
- Cell Cycle M-Phase Genes Are Highly Upregulated in Anaplastic Thyroid Carcinoma.Thyroid : official journal of the American Thyroid Association · 2017Article
- Network Modularity in Breast Cancer Molecular Subtypes.Frontiers in physiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThyroid cancer (TC) is the most common malignant cancer of the Endocrine System. Histologically, there are three main subtypes of TC: follicular, papillary and anaplastic. Diagnosing a thyroid tumor subtype with a high level of accuracy and confidence is still a difficult task because genetic, molecular and cellular mechanisms underlying the transition from differentiated to undifferentiated thyroid tumors are not well understood. A genome-wide analysis of these three subtypes of thyroid carcinoma was carried out in order to identify significant differences in expression levels as well as enriched pathways for non-shared molecular and cellular features between subtypes.
resultsInhibition of matrix metalloproteinases pathway is a major event involved in thyroid cancer progression and its dysregulation may result crucial for invasiveness, migration and metastasis. This pathway is drastically altered in ATC while in FTC and PTC, the most important pathways are related to DNA-repair activation or cell to cell signaling events.
conclusionA progression from FTC to PTC and then to ATC was detected and validated on two independent datasets. Moreover, PTX3, COLEC12 and PDGFRA genes were found as possible candidates for biomarkers of ATC while GPR110 could be tested to distinguish PTC over other tumor subtypes. The genome-wide analysis emphasizes the preponderance of pathway-dysregulation mechanisms over simple gene-malfunction as the main mechanism involved in the development of a cancer phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.